4.4 Article

Trends in osteoporosis care patterns during the COVID-19 pandemic in Alberta, Canada

Journal

ARCHIVES OF OSTEOPOROSIS
Volume 17, Issue 1, Pages -

Publisher

SPRINGER LONDON LTD
DOI: 10.1007/s11657-022-01132-7

Keywords

COVID-19; Pandemic; Osteoporosis; Care patterns; Healthcare resource utilization

Funding

  1. Amgen Canada Inc. (Amgen), Mississauga, Ontario, Canada

Ask authors/readers for more resources

This study aimed to describe the care patterns for osteoporosis during the COVID-19 pandemic in Alberta, Canada, compared to the preceding three years. The study found a decline in healthcare resource utilization, physician visits, diagnostic and laboratory tests, and treatment initiations for osteoporosis during the pandemic. Despite an increase in telehealth visits, oral bisphosphonate treatment initiations remained lower than pre-pandemic levels.
Purpose/introduction The objective of this study was to describe osteoporosis-related care patterns during the coronavirus disease 2019 (COVID-19) pandemic in Alberta, Canada, relative to the 3-year preceding. Methods A repeated cross-sectional study design encompassing 3-month periods of continuous administrative health data between March 15, 2017, and September 14, 2020, described osteoporosis-related healthcare resource utilization (HCRU) and treatment patterns. Outcomes included patients with osteoporosis-related healthcare encounters, physician visits, diagnostic and laboratory test volumes, and treatment initiations and disruptions. The percent change between outcomes was calculated, averaged across the control periods (2017-2019), relative to the COVID-19 periods (2020). Results Relative to the average control March to June period, all HCRU declined during the corresponding COVID-19 period. There was a reduction of 14% in patients with osteoporosis healthcare encounters, 13% in general practitioner visits, 9% in specialist practitioner visits, 47% in bone mineral density tests, and 13% in vitamin D tests. Treatment initiations declined 43%, 26%, and 35% for oral bisphosphonates, intravenous bisphosphonates, and denosumab, respectively. Slight increases were observed in the proportion of patients with treatment disruptions. In the subsequent June to September period, HCRU either returned to or surpassed pre-pandemic levels, when including telehealth visits accounting for 33-45% of healthcare encounters during the COVID periods. Oral bisphosphonate treatment initiations remained lower than pre-pandemic levels. Conclusions This study demonstrates the COVID-19 pandemic and corresponding public health lockdowns further heightened the crisis around the known gap in osteoporosis care and altered the provision of care (e.g., use of telehealth and initiation of treatment). Osteoporosis has a known substantial care and management disparity, which has been classified as a crisis. The COVID-19 pandemic created additional burden on osteoporosis patient care with healthcare encounters, physician visits, diagnostic and laboratory tests, and treatment initiations all declining during the initial pandemic period, relative to previous years.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available